We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The controversy surrounding Pfizer’s Cox-2 inhibitors, Celebrex and Bextra, took a new turn this week when the company was cited by the FDA for making false and misleading statements in advertisements for the painkillers.
The FDA’s Division of Drug Marketing, Advertising and Communications (DDMAC) has sent an untitled letter to Barr Pharmaceuticals informing the company it has conducted false and misleading advertising for Seasonale tablets, a daily birth control pill the company claims will help limit women’s periods to just four a year.
The FDA’s Division of Drug Marketing, Advertising, and Communications (DDMAC) has issued an untitled letter to Schering informing the company of misleading information it published recently in a professional detail aid promoting the use of Foradil Aerolizer 12 mcg.